250 related articles for article (PubMed ID: 33765101)
21. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
[TBL] [Abstract][Full Text] [Related]
22. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
[TBL] [Abstract][Full Text] [Related]
23. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
[TBL] [Abstract][Full Text] [Related]
24. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan.
Wang S; Shu Z; Tao Q; Yu C; Zhan S; Li L
Nephrology (Carlton); 2011 Nov; 16(8):767-76. PubMed ID: 21854506
[TBL] [Abstract][Full Text] [Related]
25. Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality.
Longenecker JC; Waheed S; Bandak G; Murakami CA; McMahon BA; Gelber AC; Atta MG
BMC Nephrol; 2017 Mar; 18(1):103. PubMed ID: 28347282
[TBL] [Abstract][Full Text] [Related]
26. Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease.
Nagaraju SP; Shenoy SV; Rao I; Prabhu RA; Rangaswamy D; Bhojaraja MV; Guddattu V
Saudi J Kidney Dis Transpl; 2023 Jul; 34(4):279-287. PubMed ID: 38345582
[TBL] [Abstract][Full Text] [Related]
27. Impact of hemoglobin levels on renal and non-renal clinical outcomes differs by chronic kidney disease stages: the Gonryo study.
Yamamoto T; Miyazaki M; Nakayama M; Yamada G; Matsushima M; Sato M; Sato T; Taguma Y; Sato H; Ito S
Clin Exp Nephrol; 2016 Aug; 20(4):595-602. PubMed ID: 26519375
[TBL] [Abstract][Full Text] [Related]
28. Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus.
Bartáková V; Kuricová K; Pácal L; Nová Z; Dvořáková V; Švrčková M; Malúšková D; Svobodová I; Řehořová J; Svojanovský J; Olšovský J; Bělobrádková J; Kaňková K
J Diabetes Complications; 2016; 30(7):1300-7. PubMed ID: 27324705
[TBL] [Abstract][Full Text] [Related]
29. Synergetic Association between Anemia and Hyperuricemia on New-Onset Chronic Kidney Disease in a Large Taiwanese Population Follow-Up Study.
Chen YC; Liu YH; Wu PY; Huang JC; Su HM; Chen SC; Chang JM
Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674173
[TBL] [Abstract][Full Text] [Related]
30. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Hu AM; Brown JN
Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
[TBL] [Abstract][Full Text] [Related]
31. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
Zhang X; Wan D; Yang G; Peng Q; Wang X
Int Urol Nephrol; 2019 Dec; 51(12):2273-2283. PubMed ID: 31646459
[TBL] [Abstract][Full Text] [Related]
32. Uric acid: association with rate of renal function decline and time until start of dialysis in incident pre-dialysis patients.
Nacak H; van Diepen M; de Goeij MC; Rotmans JI; Dekker FW;
BMC Nephrol; 2014 Jun; 15():91. PubMed ID: 24939671
[TBL] [Abstract][Full Text] [Related]
33. Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project.
Russo E; Viazzi F; Pontremoli R; Barbagallo CM; Bombelli M; Casiglia E; Cicero AFG; Cirillo M; Cirillo P; Desideri G; D'Elia L; Ferri C; Galletti F; Gesualdo L; Giannattasio C; Iaccarino G; Leoncini G; Mallamaci F; Maloberti A; Masi S; Mengozzi A; Mazza A; Muiesan ML; Nazzaro P; Palatini P; Parati G; Rattazzi M; Rivasi G; Salvetti M; Tikhonoff V; Tocci G; Ungar A; Verdecchia P; Virdis A; Volpe M; Grassi G; Borghi C;
J Nephrol; 2022 Jan; 35(1):211-221. PubMed ID: 33755930
[TBL] [Abstract][Full Text] [Related]
34. Time to target uric acid to retard CKD progression.
Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
[TBL] [Abstract][Full Text] [Related]
35. The role of uric acid in chronic kidney disease patients.
Hsieh YP; Chang CC; Yang Y; Wen YK; Chiu PF; Lin CC
Nephrology (Carlton); 2017 Jun; 22(6):441-448. PubMed ID: 26610276
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
[TBL] [Abstract][Full Text] [Related]
37. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor?
Nashar K; Fried LF
Adv Chronic Kidney Dis; 2012 Nov; 19(6):386-91. PubMed ID: 23089273
[TBL] [Abstract][Full Text] [Related]
38. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
Tsuruta Y; Mochizuki T; Moriyama T; Itabashi M; Takei T; Tsuchiya K; Nitta K
Clin Rheumatol; 2014 Nov; 33(11):1643-8. PubMed ID: 25048744
[TBL] [Abstract][Full Text] [Related]
39. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Levy G; Shi JM; Cheetham TC; Rashid N
Perm J; 2018; 22():17-142. PubMed ID: 30201087
[TBL] [Abstract][Full Text] [Related]
40. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
